PEGAVISION (6491) reported revenue of NT$793 million for Oct 2026, +13.0% year on year and +5.6% from the previous month. Revenue for Jan–Oct 2026 was NT$7.04 billion (+21.2% year on year).
Revenue for Oct 2026 was a record high (previous high: Nov 2023, NT$759.4 million). →
Year-on-year revenue growth: 17 months in a row. →
In Oct 2026, it ranked No. 6 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$793 million | +13.0% | +5.6% |
| Sep 2026 | NT$751 million | +20.6% | +0.1% |
| Aug 2026 | NT$750.4 million | +18.9% | +0.6% |
| Jul 2026 | NT$745.6 million | +17.4% | +3.0% |
| Jun 2026 | NT$724 million | +33.9% | +1.1% |
| May 2026 | NT$716.2 million | +36.7% | +6.2% |
| Apr 2026 | NT$674.3 million | +19.9% | +0.8% |
| Mar 2026 | NT$669.2 million | +18.2% | +20.2% |
| Feb 2026 | NT$556.9 million | +6.0% | -15.6% |
| Jan 2026 | NT$659.5 million | +31.4% | +5.5% |
| Dec 2025 | NT$624.9 million | +0.8% | +3.5% |
| Nov 2025 | NT$603.9 million | +4.4% | -13.9% |
| Oct 2025 | NT$701.6 million | +17.6% | +12.7% |
| Sep 2025 | NT$622.5 million | +7.7% | -1.4% |
| Aug 2025 | NT$631.2 million | +11.1% | -0.6% |
| Jul 2025 | NT$635 million | +23.8% | +17.5% |
| Jun 2025 | NT$540.5 million | +6.2% | +3.2% |
| May 2025 | NT$523.9 million | -14.5% | -6.9% |
| Apr 2025 | NT$562.4 million | +8.9% | -0.7% |
| Mar 2025 | NT$566.2 million | -4.3% | +7.8% |
| Feb 2025 | NT$525.3 million | -7.2% | +4.6% |
| Jan 2025 | NT$502 million | -11.5% | -19.0% |
| Dec 2024 | NT$620 million | +9.1% | +7.2% |
| Nov 2024 | NT$578.2 million | -23.9% | -3.1% |
| Oct 2024 | NT$596.6 million | -16.0% | +3.3% |
Jan–Oct 2026 cumulative: NT$7.04 billion (+21.2% YoY)
Other Biotech & Medical companies
Compare with peers: PEGAVISION vs PEC / PEGAVISION vs Lotus Pharm / PEGAVISION vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
| GKB | NT$748.3 million | -30.8% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16